Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 776-782

  Hwang, Eugene I ^a,b   Jakacki, Regina I ^c   Fisher, Michael J ^d   Kilburn, Lindsay B ^a,b   Horn, Marianna ^e   Vezina, Gilbert ^a   Rood, Brian R ^a,b   Packer, Roger J ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e Disorders of Northern Virginia   (United States)

Author keywords

Bevacizumab; Gliomas; Low grade; Pediatric; Treatment

Indexed keywords

BEVACIZUMAB; IRINOTECAN;

ANTIANGIOGENIC THERAPY; ARTHRITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLIOMA; HOSPITALIZED CHILD; HUMAN; HYPERTENSION; INFANT; LETHARGY; LONG TERM CARE; MALE; MENTAL DISEASE; MONOTHERAPY; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84874957098     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24297     Document Type: Article

References (25)

1. Statistical report: Primary brain tumors in the United States CBTRUS., Illinois:, -H, Published by the Central Brain Tumor; Registry of the United States. 2010.
2. Dalla Via P, Opocher E, Pinello ML, et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol 2007; 9: 430-437.
3. Beebe DW, Ris MD, Armstrong FD, et al. Cognitive and adaptive outcome in low-grade pediatric cerebellar astrocytomas: Evidence of diminished cognitive and adaptive functioning in National Collaborative Research Studies (CCG9891/POG 9130). J Clin Oncol 2005; 23: 5198-5204.
4. Fouladi M, Wallace D, Langston JW, et al. Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 2003; 97: 1084-1092.
5. Mishra KK, Squire S, Lamborn K, et al. Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update. J Neurooncol 2010; 100: 121-127.
6. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008; 26: 1338-1345.
7. Wallner KE, Gonzales MF, Edwards MS, et al. Treatment results of juvenile pilocytic astrocytoma. J Neurosurg 1988; 69: 171-176.
8. Fisher PG, Tihan T, Goldthwaite PT, et al. Outcome analysis of childhood low-grade astrocytomas. Pediatr Blood Cancer 2008; 51: 245-250.
9. Merchant TE, Conklin HM, Wu S, et al. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: Prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 2009; 27: 3691-3697.
10. Armstrong GT, Conklin HM, Huang S, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro Oncol 2011; 13: 223-234.
11. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86: 747-754.
12. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52: 791-795.
13. von Hornstein S, Kortmann RD, Pietsch T, et al. Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: Report from the HIT-LGG 199 trial. Pediatr Blood Cancer 2011; 56: 1046-1054.
14. Massimino M, Spreafico F, Riva D, et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. J Neurooncol 2010; 100: 65-71.
15. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol 2007; 9: 161-168.
16. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 2012; 30: 1358-1363.
17. Qaddoumi I, Sultan I, Broniscer A. Pediatric low-grade gliomas and the need for new options for therapy: Why and how? Cancer Biol Ther 2009; 8: 4-10.
18. Gururangan S. Phase II study of Bevacizumab plus Irinotecan in Children with Recurrent, Progressive, or Refractory Low Grade Gliomas. PBTC trial 022-Personal Communication.
19. Warren KE, Goldman S, Pollack IF, et al. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011; 29: 324-329.
20. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: A report from the Children's Oncology Group. Cancer 2007; 110: 1542-1550.
21. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405.
22. Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 3069-3075.
23. Jacob K, Quang-Khuong DA, Jones DT, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011; 17: 4650-4660.
24. Tabori U, Vukovic B, Zielenska M, et al. The role of telomere maintenance in the spontaneous growth arrest of pediatric low-grade gliomas. Neoplasia 2006; 8: 136-142.
25. Reismuller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer 2010; 54: 681-686.